Sanofi (China)

Recent papers from Sanofi (China)

1. Efficacy of Dupilumab in Patients From China With Persistent Type 2 Asthma With and Without an Allergic PhenotypeClinical & Experimental Allergy · 2026
2. Impact of Dupilumab Therapy on Skin Barrier Function in Patients With Moderate‐to‐Severe Atopic Dermatitis: A Phase IV, Non‐Randomized, Open‐Label, Parallel‐Group Clinical StudyMedComm · 2026
3. Treatment patterns, healthcare utilization, and healthcare costs in patients with newly diagnosed type 1 diabetes: a retrospective real-world study in Tianjin, ChinaJournal of Medical Economics · 2026
4. Treatment Patterns and Clinical Outcomes Among Chinese Patients With Newly Diagnosed Multiple Myeloma: A Multicenter Retrospective Study ( CHAMP ‐ MM )Cancer Medicine · 2026
5. Uncontrolled Status, Disease Burden, and Associated Risk Factors Among Patients with Asthma Receiving Medium-to-High Dose ICS or ICS/LABA: A Retrospective AnalysisAdvances in Therapy · 2026
6. Efficacy and Safety of iGlarLixi Versus IDegAsp by Baseline Age, Disease Duration and HbA1c in Chinese People With Type 2 Diabetes: Post Hoc Analyses of the Soli‐D StudyDiabetes Obesity and Metabolism · 2026
7. Impact of iGlarLixi on Glycaemic Control Depth and Variability in Asian Pacific People With Type 2 Diabetes: A Post Hoc Analysis of LixiLan ‐O‐ AP and LixiLan ‐L‐ CNDiabetes Obesity and Metabolism · 2026
8. Efficacy and Safety of Dupilumab in Chinese Adult Patients With Chronic Rhinosinusitis With Nasal Polyps: A Randomized, Placebo‐Controlled, Phase III TrialAllergy · 2026
9. Impact of Time of Injection on the Efficacy and Safety of iGlarLixi Versus IDegAsp in Chinese People With Type 2 Diabetes: Exploratory Analysis of the Soli‐D StudyDiabetes Obesity and Metabolism · 2026
10. Moderate and Severe Exacerbations and Healthcare Resource Utilization in Chinese Patients with COPD on Triple Therapy: A Retrospective Database StudyAdvances in Therapy · 2026
11. C14-05 Efficacy of Rilzabrutinib on Asthma Control Based on Prior Exacerbation History: Pooled Results From a Double-Blind, Placebo-Controlled, Phase 2 StudyAmerican Journal of Respiratory and Critical Care Medicine · 2026
12. C14-06 Amlitelimab (an Anti-ox40 Ligand Antibody) Significantly Reduces Blood Biomarkers Involved in the Pathogenesis of AsthmaAmerican Journal of Respiratory and Critical Care Medicine · 2026
13. B32-04 Efficacy of Rilzabrutinib on Asthma Quality of Life: Pooled Results From a Double-blind Placebo-controlled Phase 2 StudyAmerican Journal of Respiratory and Critical Care Medicine · 2026
14. Positive Predictive Value of Respiratory Infection Diagnoses in The Danish National Patient Registry: a Post-hoc Validation Analysis of the DANFLU-1 TrialInternational Journal of Infectious Diseases · 2026
15. A phase I, single-arm, open-label, dose-escalation, multicenter study of SAR445419, an off-the-shelf, ex vivo expanded allogeneic natural killer cell product, in participants with relapsed or refractory acute myeloid leukemiaCancer Immunology Immunotherapy · 2026
16. The Risk of Disease Progression of Type 1 Diabetes in First‐Degree Relatives of People With Type 1 Diabetes: Design and Rationale of a Prospective, Longitudinal Study in ChinaDiabetes Obesity and Metabolism · 2026
17. Alglucosidase alfa demonstrates effectiveness and safety in Chinese patients with late-onset Pompe disease: A multi-center prospective studyMolecular Genetics and Metabolism · 2026
18. Intensity of Serum Phosphate Lowering in Patients With Nondialysis Dependent Chronic Kidney Disease and HyperphosphatemiaJournal of Renal Nutrition · 2026
19. Effects of age and disease duration on the glycaemic outcomes and safety of insulin glargine 300 U/ mL in people with type 2 diabetes in China: A post‐hoc analysis of the INITIATION studyDiabetes Obesity and Metabolism · 2026
20. Baseline Demographics, Clinical Characteristics, Treatment Patterns, and Burden of Atopic Dermatitis in Patients Initiating Dupilumab: A Retrospective, Observational Study Using Data From a Real‐World Registry (CORNERSTONE)Dermatologic Therapy · 2026